{"name":"Ixaka Ltd","slug":"ixaka-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9iMHJCZW9TUUNycDEtR1loaEpNZWEyUEhvUG1zTGF6VV81RUxhR1ExWV83dmFSWTdObndkT1NFalVXckRCTXlaSGY1M3FEZXZMT0ZV?oc=5","date":"2022-06-27","type":"pipeline","source":"FirstWord Pharma","summary":"Ixaka and Minaris Regenerative Medicine Sign Tech Transfer and GMP Manufacturing Agreement for Lead Cell Therapy Candidate REX-001 - FirstWord Pharma","headline":"Ixaka and Minaris Regenerative Medicine Sign Tech Transfer and GMP Manufacturing Agreement for Lead Cell Therapy Candida","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPZFRaTzlUM3dqVzNLdzdGVFRZeUdXTktfdjB4MWpMZUVRV1d1cXFzZjdrRUJSQ1JrRm5VMEpPU1VGTXhSWlM3NlZPNmREalFaT0hxY0FDN0JkNFhaZFhqR1NHbHlsUUFhQ2JyWGFScEg0UWJ0WEh4QzY4SW9HRHVqaHlnOVJ6X3hiQWlhLTlFNFVXUVE1T1E?oc=5","date":"2022-03-08","type":"regulatory","source":"PharmaTimes","summary":"Cell door: EMA grants ATMP classification to CELTIC-19 - PharmaTimes","headline":"Cell door: EMA grants ATMP classification to CELTIC-19","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPV183cllsakxCUVh3SjNaaWI5bDZLTWEzdFlia1lINEhUZGN2MGNOelJuZE42UHJXYVhkWXBzWnQ0TVNHdW05UmI2MU9teUo4NnZCOGxMU2JSWHl4TkUtQzU0LUNxMDBDREJqX2RLZGZZaV9WeUZoNjFnYVlLWkFoVTI0VDZzbGVaR1E1YjVuT29UUUxSSEhOZjF3?oc=5","date":"2021-09-08","type":"trial","source":"PharmaTimes","summary":"Positive interim data for Ixaka’s lead ‘multi-cell’ therapy - PharmaTimes","headline":"Positive interim data for Ixaka’s lead ‘multi-cell’ therapy","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}